Have a personal or library account? Click to login
Open Access
|Oct 2024

Abstract

DiGeorge syndrome is a primary immunodeficiency caused by the abnormal growth of the third and fourth pharyngeal pouches throughout prenatal development. It is typified by a triad: hypocalcemia due to hypoparathyroidism, some heart defects, and thymic hypoplasia or aplasia. This syndrome is associated with a microdeletion in the chromosomal region 22q11.2. DiGeorge syndrome together with other dysfunctions like velo-cardio-facial syndrome and Takao syndrome have overlapping traits. The symptoms are hidden under the name CATCH22. It describes signs like a cardiac defect, abnormal facies, thyme hypoplasia, cleft palate, hypocalcemia, and chromosome 22q11.2 deletions. Its incidence is estimated to be approximately 1:3000 live births. The disorder is inherited in an autosomal dominant pattern or arises from de novo mutation. 22q11.2 microdeletion is associated with an increased risk of developing mental diseases, including schizophrenia. In the general population, 1-2% of people suffer from schizophrenia. In DiGeorge syndrome this ratio is much higher, around 25-30%. Nowadays, the fluorescence in situ hybridization (FISH) is a gold standard method for the diagnosis of microdeletion syndrome. Currently, there is no effective therapy to prevent the development of the disease.

DOI: https://doi.org/10.2478/phr-2023-0023 | Journal eISSN: 2084-0535 | Journal ISSN: 1734-7009
Language: English
Page range: 73 - 82
Submitted on: Oct 12, 2023
Accepted on: Oct 27, 2023
Published on: Oct 12, 2024
Published by: Polish Hyperbaric Medicine and Technology Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year

© 2024 Wiktoria Czuj, published by Polish Hyperbaric Medicine and Technology Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.